Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Aronex reports responses in phase II trial of Atragen as treatment of NHL

June 30, 1999

New compounds from Merck inhibit posttranslational farnesylation of proteins

June 30, 1999

FeRx's targeted carrier tested in doxorubicin delivery to liver cancer patients

June 30, 1999

QLT terminates collaboration with Beaufour Ipsen

June 30, 1999

Continued focus at Merck on inhibitors of protein farnesyltransferase

June 29, 1999

Ligand submits NDA for Targretin capsules and reports positive interim data from psoriasis study

June 29, 1999

Magainin begins phase II testing of squalamine

June 29, 1999

Ethyol approved by FDA for radiation-induced dry mouth

June 28, 1999

Et-743, a potent anticancer agent with a complex, unique mechanism of action

June 28, 1999

BioInvent will supply Theragyn for Antisoma

June 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...